FLOVENT HFA 50 MCG
FLUTICASONE PROPIONATE : 50 MCG · DIN 02244291 · GLAXOSMITHKLINE INC
Health Canada status: MARKETED
What is FLOVENT HFA?
FLOVENT HFA 50 MCG contains FLUTICASONE PROPIONATE : 50 MCG. It is listed in the Health Canada Drug Product Database under DIN 02244291, held by GLAXOSMITHKLINE INC, supplied as METERED-DOSE AEROSOL for ORAL ; INHALATION administration. Health Canada currently lists it as marketed, status dated 20-Dec-2001. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02244291 |
|---|---|
| Brand name | FLOVENT HFA |
| Generic / active ingredient | FLUTICASONE PROPIONATE : 50 MCG |
| Manufacturer | GLAXOSMITHKLINE INC |
| Strength | 50 MCG |
| Dosage form | METERED-DOSE AEROSOL |
| Route of administration | ORAL ; INHALATION |
| Schedule | Prescription |
| ATC code | R03BA05 FLUTICASONE |
| AHFS class | 68:04.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 20-Dec-2001 |
| Original market date | 2001-12-20 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code R03BA05 FLUTICASONE. 12 of 27 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-FLUTICASONE HFA | 125 MCG | METERED-DOSE AEROSOL | APOTEX INC | MARKETED | DIN 02526557 |
| APO-FLUTICASONE HFA | 250 MCG | METERED-DOSE AEROSOL | APOTEX INC | MARKETED | DIN 02510987 |
| APO-FLUTICASONE HFA | 50 MCG | AEROSOL, METERED DOSE | APOTEX INC | MARKETED | DIN 02528428 |
| FLOVENT DISKUS | 100 MCG | POWDER | GLAXOSMITHKLINE INC | MARKETED | DIN 02237245 |
| FLOVENT DISKUS | 250 MCG | POWDER | GLAXOSMITHKLINE INC | MARKETED | DIN 02237246 |
| FLOVENT DISKUS | 500 MCG | POWDER | GLAXOSMITHKLINE INC | MARKETED | DIN 02237247 |
| FLOVENT HFA | 125 MCG | METERED-DOSE AEROSOL | GLAXOSMITHKLINE INC | MARKETED | DIN 02244292 |
| FLOVENT HFA | 250 MCG | METERED-DOSE AEROSOL | GLAXOSMITHKLINE INC | MARKETED | DIN 02244293 |
| PMS-FLUTICASONE HFA | 125 MCG | METERED-DOSE AEROSOL | PHARMASCIENCE INC | MARKETED | DIN 02503123 |
| PMS-FLUTICASONE HFA | 250 MCG | METERED-DOSE AEROSOL | PHARMASCIENCE INC | MARKETED | DIN 02503131 |
Who else supplies FLUTICASONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. FLUTICASONE appears in 9252 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.